Toronto, Ontario – May 12, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has signed a Clinical Research Agreement (“CRA”) with Princess Margaret Cancer Centre, University Health Network (“UHN”) to conduct a Phase Ib clinical study for the indication of Non-Muscle Invasive Bladder Cancer (“NMIBC”).
The clinical study entitled, “A Phase Ib Trial of Intravesical Photodynamic Therapy in Patients with Non-Muscle Invasive Bladder Cancer at High Risk of Progression Who Are Refractory to Therapy with Bacillus Calmette-Guerin (“BCG”) and Who Are Medically Unfit for or Refuse a Cystectomy”, will be conducted by the Department of Urology at UHN, under the guidance of clinical principal investigator, Dr. Girish Kulkarni.
Dr. Girish Kulkarni, uro-oncologist at UHN stated, “I have worked closely with Theralase’s team of researchers over the last nine months in the development of the clinical protocol, investigator’s brochure and informed consent and am impressed with the pre-clinical scientific research that Theralase has brought to the table in support of this clinical study. I look forward to leading the clinical study and working with other urologists throughout Ontario to help enroll their patients in the study.”
Dr. Michael Jewett, uro-oncologist at UHN stated that, “Theralase has completed numerous strategic milestones leading up to this Phase Ib clinical study and I have been very pleased with the speed and capability of the researchers to accomplish a great many tasks in a very short period of time. The Theralase scientific research has been validated through peer reviewed publications and supports the commencement of a Phase Ib clinical study, pending approval by Health Canada of the Investigational Testing Authorization (“ITA”), for the medical laser used to activate the lead PDC, TLD-1433.”
Roger Dumoulin-White, President and CEO, Theralase stated, “The execution of the CRA with UHN to conduct a Phase Ib clinical study for patients afflicted with NMIBC allows the ability to commence enrolling patients immediately upon Health Canada approval of the ITA, expected in late 2Q2016. The Company looks forward to introducing this game changing technology to the world.”
About Theralase Technologies Inc.
Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs”), which are able to localize to cancer cells and then when laser light activated, effectively destroy them.
Additional information is available at www.theralase.com and www.sedar.com .
This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com